Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma
BackgroundPrimary central nervous system lymphoma (PCNSL) is an uncommon variant of non-Hodgkin lymphoma (NHL) with high aggressiveness and poor prognosis. Although complete remission (CR) could be achieved with therapy, some patients remain refractory or recurrently with a worse response to salvage...
Main Authors: | Yu Yang, Qing Li, Jingjing Ma, Hui Kang, Zhiguang Lin, Yang Wang, Yan Ma, Bobin Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1098785/full |
Similar Items
-
Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study
by: Jingjing Ma, et al.
Published: (2022-07-01) -
Assessment of Effectiveness and Adverse Effect of New Combination Chemotherapy (irinotecan, cisplatin, and dexamethasone) in Relapse and Refractory Hodgkin Lymphoma
by: Mahdi Tabarraee, et al.
Published: (2023-07-01) -
Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
by: Nikhil Yegya-Raman, et al.
Published: (2023-03-01) -
Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era
by: Cheng Huang, et al.
Published: (2024-01-01) -
GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study
by: Mani Ramzi, et al.
Published: (2015-03-01)